Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The primary goal is to evaluate the efficacy of osimertinib (AZD9291), in terms of the
objective response rate in patients with advanced non-squamous NSCLC with EGFR mutations and
the EGFR T790M mutation at diagnosis as defined by RECIST 1.1 criteria.
Safety and efficacy will also be measured.